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events for morbidity and mortality, respectively. Explanatory covari-Comparison of mortality in ESRD patients on convective and diffusive
ates were age, gender, and comorbidities; dialysis modality was testedextracorporeal treatments.
as a time-dependent covariate.Background. The aim of this study was to evaluate the effect of
Results. The relative risk (RR) for CTS surgery was significantlyconvective [hemodiafiltration (HDF) or hemofiltration (HF)] versus
higher in older patients [RR 5 1.04 per year of age on admission todiffusive treatments [hemodialysis (HD)] on end-stage renal disease
RRT, 95% confidence interval (CI) 1.02 to 1.06; P 5 0.0001], in diabet-(ESRD) patient mortality and dialysis-related amyloidosis (DRA) us-
ics (RR 5 2.63, 95% CI 1.30 to 5.31; P 5 0.0007), and in patients withing data from the Lombardy Registry.
heart disease (RR 5 5.36, 95% CI 2.27 to 12.68 P 5 0.0001). AdjustingMethods. For this purpose, 6,444 patients (aged 56.4 6 15.6 years,
for age and diabetic status, the RR for CTS surgery was 42% lowerfemales 39.5%, diabetics 10.6%) who started renal replacement ther-
in the patients treated with HDF or HF (RR 5 0.58, 95% CI 0.35 toapy (RRT) on HD, HDF, or HF between 1983 and 1995 were consid-
0.95, P 5 0.03). The RR for mortality, adjusted for age, gender, andered. A total of 1,082 patients were treated with HDF or HF (first
comorbidities, was 10% lower in patients treated with HDF or HFchoice in the case of 188), with a median follow-up of 29.7 months.
(RR 5 0.90, 95% CI 0.76 to 1.06; P 5 NS).The median follow-up of the 6,298 patients on HD (first choice in the
Conclusion. These results support the hypothesis that convective treat-case of 6256) was 22.4 months. The time of survival on dialysis to
ments are associated with a nonsignificant trend toward better survivalcarpal tunnel syndrome (CTS) surgery was evaluated as a hard marker
and significantly delay the need for CTS surgery. An older age andof DRA morbidity. Survival was compared by means of the Cox propor-
the presence of diabetes and heart disease are other important risktional regression hazards model, using CTS surgery and all deaths as
factors for CTS surgery. These results could have an important clinical
impact given the relevance of DRA in dialysis patient morbidity.
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and improved technology in the treatment of water and following the example of an analysis performed on heart
transplant patients [7].in the production of high-quality dialysate. In the past,
When considering CTS as the end point, the patientsthe use of high-flux membranes was strictly associated
with a history of decompression surgery before the be-with convective techniques such as hemofiltration (HF)
ginning of RRT were excluded from the analysis. Patient[3] and hemodiafiltration (HDF) [4], and it is only re-
death, transfer to a dialysis unit out of Lombardy, orcently that high-flux dialyzers have begun to be used in
a switch to peritoneal dialysis or renal transplantationhemodialysis (HD) treatment, possibly because dialysate
before CTS surgery was regarded as censored informa-purity can now be carefully monitored.
tion, as was extracorporeal dialysis without CTS surgeryThe aim of this study was to examine the effects of
by the final observation date (December 31, 1995). Thehigh-flux membranes on mortality and the occurrence
explanatory covariates were age, gender, underlying re-of the carpal tunnel syndrome (CTS) surgery, considered
nal disease (nondiabetic and diabetic nephropathy), andas a hard marker of DRA morbidity. Given the long-
comorbidy.term nature of the outcome and the fact that the use of
Analyzing patient survival, transfer to a dialysis unithigh-flux HD in Lombardy was only recently increased,
out of Lombardy, or a switch to peritoneal dialysis orwe decided to compare HF and HDF (convective treat-
renal transplantation was regarded as censored informa-ments) versus standard HD (diffusive treatment).
tion, as was ongoing extracorporeal dialysis on the final
observation date (December 31, 1995). All of the deaths
METHODS that occurred within the first two months of a change in
dialytic technique were included as deaths on the firstData collection
treatment. The independent variables tested for ad-The data used in this analysis came from the Dialysis
justing the death rate of the two treatments were age onand Transplant Lombardy Registry, and included pa-
admission to RRT, gender, underlying disease (nondia-tients who started RRT for end-stage renal disease
betic or diabetic nephropathy), and baseline comorbid(ESRD) between January 1, 1983, and December 31,
conditions (heart disease, cerebrovascular disease such1995. The Registry was begun in 1982 under the aegis
as stroke or transient ischemic attack, peripheral vascularof the Lombardy Regional Section of the Italian Society
disease, neoplasm, cirrhosis, severe malnutrition).of Nephrology and the Regional Health Department.
In both analyses, the strategy suggested by Collett forData were collected at the end of each year (100% center
model selection was used to identify the set of explana-
response rate). The 10,612 incident patients between
tory variables that had the potential for being included
1983 and 1995 were drawn from the 44 Lombardy dialysis in the linear component of the model [8]. The calcula-
units. A detailed study concerning the 1983–1992 dialysis tions for Cox-proportional hazards model with a time-
and transplantation results in Lombardy has been pub- dependent covariate were made using the TIME PRO-
lished previously [5]. The Lombardy Registry tracks the GRAM and COXREG SURVIVAL procedures of the
modality of treatment and the outcome of ESRD pa- SPSS version 7.5 software package [9]. The contribution
tients (mortality, hospitalization, CTS, etc.) living as of of the covariates to explain the dependent variable was
January 1, 1983, and the incident ESRD patients from assessed by means of a two-tailed likelihood ratio test,
the same date. We defined the onset of CTS by the date with P values of less than 0.05 being considered significant.
of the first decompression surgery.
Statistical methods RESULTS
Cox proportional hazards regression models [6] were Patient characteristics
used to evaluate the mortality and morbidity of the A total of 6,444 out of 10,612 patients who started
ESRD patients treated with convective (HF and HDF) RRT between January 1, 1983 and December 31, 1995
and diffusive treatments (HD). The dates of the two end were on extracorporeal treatment at one month after
points (first CTS decompression surgery and death) were the onset of ESRD. Their mean age (6 sd) was 56.4 6
recorded. The patients selected for this study were all 15.6 years, ranging from 50.5 6 14.4 in 1983 to 60.7 6
on extracorporeal treatment, the modality of which was 15.4 in 1995. There was an excess of male patients
based on the treatment received after the first month of (60.5%), which was without any significant change from
ESRD. Patient survival was tracked on the basis of that 1983 to 1995. The proportion of new patients with diabe-
treatment modality, which may be either diffusive (HD) tes continuously increased over the study period from
or convective (HF and HDF). Because the dialysis tech- 5.9% in 1983 to 14.1% in 1995 (average 10.6%). Malig-
nique was not a constant during the follow-up of patients nancy was the most frequent comorbid condition (5.6%)
on extracorporeal treatment, it was tested in the model at the onset of ESRD, followed by heart disease (coro-
nary heart disease or myocardial infarction; 5.3%), pe-as a time-dependent covariate. This approach was chosen
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Fig. 1. Schematic diagram showing the number
of patients selected for convective or diffusive
extracorporeal treatment and the number who
were subsequently switched from one treatment
to the other.
ripheral vascular disease (3.0%), and cerebrovascular
disease (2.7%). Cirrhosis was present in 1.3% of these
patients, and severe malnutrition was in only 0.3%.
Extracorporeal treatments
The switches between diffusive and convective tech-
niques during the 13-year follow-up period are shown
in Figure 1. On day 30 after the beginning of RRT, 6,256
of the 6,444 patients were receiving diffusive treatment
(HD), and 188 patients convective treatment (HDF or
HF). Both groups of patients were treated with the tech-
nique prescribed on day 30 for a median of 22.4 months.
During the follow-up, 894 patients in the HD group were
moved to convective treatment after a median of 18.5
months, and 42 in the convective group were moved to
HD after a median of 13.3 months. In total, 1,082 patients
were treated convectively, and 6,298 were treated diffu-
Fig. 2. Kaplan-Meyer survival curve of ESRD patients (outcome: car-sively for at least a period of their RRT follow-up, with
pal tunnel syndrome surgery) admitted to extracorporeal treatment inthe median follow-up being 29.7 and 22.4 months, respec-
Lombardy between 1983 and 1995.
tively. Dialyzers were never reused, because reuse is
forbidden by law in Italy.
Patient morbidity then decreased to 91% at 10 years and 83% at 12 years.
One hundred eight out of 6,444 patients underwent The relative risk (RR) for CTS surgery was 41% lower
CTS surgery during follow-up. At a dialysis center level, in patients on convective treatment (RR 5 0.59, 95%
the median rate of CTS surgery was 0.43 per 100 patient CI 0.36 to 0.96, P 5 0.034). After adjusting for the known
years (ranging from 0 in the relatively new centers to risk factor of age, the RR reduction became 43% (RR 5
1.26 per 100 in the older ones). Figure 2 shows the 0.57, 95% CI 0.35 to 0.94, P 5 0.027); adjusting for both
Kaplan-Meyer cumulative survival curve (free of CTS age and diabetic status, it became 44% (RR 5 0.56, 95%
surgery) of these patients. The cumulative survival was CI 0.33 to 0.95, P 5 0.0232). The results based on the
Cox proportional hazards model (without interaction),nearly 100% until the fourth year of follow-up, and it
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Table 1. Relative risk rates for carpal tunnel syndrome surgery by demographic and comorbid factors according to Cox’s main effect model
in the patients treated with convective and diffusive extracorporeal treatments
Relative death rate
Variable Reference mean (95% C.I.) P value
Age Per year 1.043 (1.021–1.065) 0.0001
Gender Female — NS
Diabetes status Non-diabetes 2.633 (1.304–5.316) 0.0007
Heart disease Absent 5.364 (2.270–12.682) 0.0001
Peripheral arteriopathy Absent — NS
Cerebrovascular disease Absent — NS
Cirrhosis Absent — NS
Severe malnutrition Absent — NS
Other risk Absent — NS
Malignancy Absent — NS
Extracorporeal dialysis technique Hemodialysis 0.578 (0.352–0.947) 0.03
Fig. 3. Significant covariates and relative risks for
carpal tunnel syndrome surgery.
which takes into account not only the known or sus- the presence of heart disease, and did not confirm the
role of the convective treatments, probably because of thepected risk factors but also all the list of comorbid condi-
tions (heart disease, cerebrovascular disease such as stroke small number of patients that received only convective
treatment (N 5 146). The proportionality of the covariatesor transient ischemic attack, peripheral vascular disease,
neoplasm, cirrhosis, and severe malnutrition) are given was ensured by using the Martingales residuals plot, which
did not show any significant deviation from linearity.in Table 1. The RR for CTS surgery was significantly
higher in elderly patients (RR 5 1.04 per year, 95% CI
Patient survival1.02 to 1.06, P 5 0.0001), in diabetics (RR 5 2.63, 95%
CI 1.30 to 5.32, P 5 0.007) and five times greater in Thirty-three percent of the 6,444 patients died. Figure
4 shows the Kaplan-Meyer cumulative survival curve ofpatients with heart disease (coronary artery disease, pre-
vious myocardial infarction, severe heart failure; RR 5 these patients; the cumulative survival was 89.3% at one
year, 81.4% at two years, 60.9% at five years, and 36.8%5.36, 95% CI 2.27 to 12.68, P 5 0.0001). After adjusting
for age, diabetic status, and the presence of heart disease, at 10 years. The unadjusted relative mortality risk of the
patients treated with HDF or HF, in comparison withthe RR for CTS surgery was a significant 42% lower in
patients treated with HDF or HF than in those on HD those treated with HD, was 0.970 (95% CI 0.827 to 1.137,
P 5 NS). The results based on the Cox proportional(RR 5 0.58, 95% CI 0.35 to 0.95, P 5 0.03; Fig. 3).
An additional analysis was made of those patients who hazards model (without interaction) are given in Table
2. The adjusted mortality risk for all patients on dialysisdid not change the modality of treatment (using as pre-
dictor in Cox proportional hazard model the modality was higher for older patients (RR 5 1.06 per year; P 5
0.0001). The death risk for males was significantly higherprescribed 30 days after the onset of ESRD). The analysis
results were similar for the covariate’s age, diabetes, and than for females (RR 5 1.21, P 5 0.0011). Compared
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Table 2. Relative risk rates for death by demographic and comorbid factors according to Cox’s main effect model in the patients treated
with convective and diffusive extracorporeal treatments
Relative death rate
Variable Reference mean (95% C.I.) P value
Age Per year 1.059 (1.054–1.065) 0.0001
Gender Female 1.210 (1.079–1.358) 0.0011
Diabetes status Non-diabetes 2.061 (1.767–2.403) 0.0001
Heart disease Absent — NS
Peripheral arteriopathy Absent — NS
Cerebrovascular disease Absent — NS
Cirrhosis Absent — NS
Severe malnutrition Absent 2.280 (0.848–6.132) 0.10
Other risk Absent 1.476 (1.211–1.798) 0.0001
Malignancy Absent — NS
Extracorporeal dialysis technique Hemodialysis 0.900 (0.766–1.057) NS
be addressed to improve not only survival but also the
quality of life of the patients.
Because the number of patients who have received
HD for more than 10 years has increased markedly, a
frequent complication is the deposition of amyloid on
bones and joints that causes CTS and polyarthralgia. The
importance of the problem is amplified by the increasing
age of the patients admitted to chronic HD. As Van
Ypersele de Strihou et al pointed out, age is a very
important independent risk factor in rapidly developing
DRA, which greatly reduces the quality of life of dialysis
patients [12].
Standard diffusive HD therapy only partially responds
to the purification needs of uremic patients, and thus the
onset of some complications can be considered “natural
events” during the course of follow-up. DRA is often
underevaluated, although its relationship with the qual-Fig. 4. Kaplan-Meyer survival curve of ESRD patients admitted to
extracorporeal treatment in Lombardy between 1983 and 1995 selected ity of life of ESRD patients is well known, and it may
for the study. even reduce their survival. DRA is mainly due to the
retention of native (intact) and AGE-modified b2-micro-
globulin and its subsequent deposition [13]. Renal re-
placement therapies clear b2-microglobulin to differentwith those who were nondiabetic, the death rates of
extents, with considerable amounts being removed bydiabetic patients was 2.06 times higher (P 5 0.0001).
only high-flux membranes [8]. Consequently, predialysisThese analyses failed to show any significant relationship
levels of b2-microglobulin are lower in patients treatedbetween survival and heart diseases, cerebrovascular dis-
with high-flux membranes [2], regardless of the tech-eases, cirrhosis, and severe malnutrition. The risk of mor-
nique used (high-flux HD or HDF). Hakim et al foundtality was approximately 2.28-fold higher in patients with
that membrane biocompatibility is an important factorsevere malnutrition, but this too was only of borderline
in reducing the rate of b2-microglobulin production [14].significance (P 5 0.10). According to this model, the
The results of Locatelli et al suggest that the effect ofadjusted death rate for the patients on extracorporeal
the removal of b2-microglobulin by convection and thetreatment with convective modalities was not statistically
adsorption may be greater than the reduced productiondifferent to that of patients treated with HD (RR 5
of b2-microglobulin attributable to membrane biocom-0.900, 95% CI 0.766 to 1.057, P 5 0.19).
patibility [2].
However, no differences in serum b2-microglobulin
DISCUSSION concentrations have been found between dialysis patients
with and without amyloidosis, suggesting that other fac-The survival of dialysis patients is increasing world-
tors also contribute to amyloid deposition [15–17]. How-wide, and the survival of patients treated in Lombardy
is quite good [10, 11]. Our efforts should therefore now ever, large-sized clinical trials and registry-based epide-
Locatelli et al: Convective treatments and ESRD patient outcome 291
miological analyses are inappropriate for investigating ated with a lower prevalence of dialysis-associated ar-
these factors further because of the need for sophisti- thropathy. These data have been confirmed by Bonomini
cated evaluations such as kinetic studies, which can only et al, who retrospectively analyzed 122 patients on cellu-
be adopted in the case of small, problem-oriented trials. losic or synthetic membranes [23]. In a very recent retro-
The clinical manifestation of CTS is one of the clearest spective study, Koda et al found that switching 819 pa-
symptoms of DRA. The requirement for decompression tients from conventional to high-flux membranes led to
surgery is usually based not only on EMG results, but a reduction in the RR of CTS surgery of 49% [24], thus
also mainly on the importance of the clinical symptoms. confirming the results of a previous small randomized
Accordingly, it is not surprising that the probability of trial (involving 20 patients moved to high-flux polysul-
CTS surgery was only 5% in the Lombardy patients after fone) by Kuchle et al [25].
eight years of extracorporeal treatment. The fact that A recognized risk factor for DRA is the age of the
the rate of occurrence of CTS surgery is similar in the patient at the onset of RRT. As already pointed out,
Lombardy centers reflects the generally homogeneous Van Ypersele de Strihou et al have demonstrated that
approach of Lombardy nephrologists towards the indica- age is a major risk factor for both CTS and bone cysts,
tion for surgery. These results are similar to those found regardless of the time on HD and membrane type [12].
by Charra, Calemard and Laurent in a retrospective This conclusion was subsequently confirmed by the same
study of 497 patients [18]. group [26] and by Koda et al [24]. Our study confirmed
As it has been suggested that there may be a relation- the role of age as a risk factor, but when age at the
ship between the need for carpal tunnel syndrome sur- beginning of RRT was taken into account, the RR of
gery and malignancies, such as leukemia and myeloma, CTS surgery remained significantly lower (43%) in the
we investigated the distribution of malignancies in this patients treated with convective treatments.
population and found that none of the 79 patients with Another potential risk factor in DRA is diabetes, al-
such malignancies underwent CTS surgery. The same though diabetic nephropathy was not detected as a sig-
was true of the 28 patients with amyloidosis as the pri- nificant risk factor for DRA in the studies of Lehnert et
mary renal disease. However, we emphasize that clini- al [27], Jadoul et al [19], and Koda et al [24]. The role
cally manifested CTS is only the tip of the iceberg of of diabetic status as a predictor of CTS surgery was
DRA, and very interesting findings from a recent pro- evaluated in the Cox model, which showed a significantly
spective postmortem study of Jadoul et al support this higher RR for diabetic ESRD patients (RR 5 2.63).
opinion [19]. When age and diabetic status were considered together,
The fact that our study showed a significantly lower the relationship between the extracorporeal dialysis
RR for the development of CTS requiring surgery in
technique and CTS surgery still remained significant,patients on convective treatments could have a very im-
with a 44% lower RR for those patients treated with HFportant clinical impact. Keeping in mind the difficulties
or HDF. This result may be explained by the higherin detecting the symptoms of DRA, it is not surprising
statistical power of this large-sized epidemiologicalthat previous studies of this subject have led to conflicting
study.results. Chanard et al reported a significantly lower actu-
A stepwise procedure testing the association with thearial risk of CTS in 31 patients treated with high-flux
comorbid conditions collected by the Lombardy Registrydialyzers of polyacrylonitrile (PAN) than in 54 cupro-
showed that cardiac status was a significant predictor ofphane-treated patients [20]. In a retrospective case-con-
CTS surgery, that is, in addition to age and diabetic statustrol study based on EDTA Registry data, Brunner et al
our patients with heart disease had a fivefold highershowed a lower but not statistically significant prevalence
risk of CTS surgery. Although a statistical associationof CTS in patients treated with a high-flux dialyzer
between a tested predictor and outcome does not mean(PAN) in comparison with a matched control group ex-
a cause–effect relationship, it is interesting to note thatclusively dialyzed with cellulosic membranes [21]. How-
the relationship between the extracorporeal dialysisever, the methodological drawbacks of the Brunner arti-
technique and CTS surgery was not affected by the ad-cle [21] have been underlined by Van Ypersele de
justment for this comorbid factor. The RR of CTS sur-Strihou et al [12], who retrospectively analyzed 221 pa-
gery in patients on convective treatments was 0.578 ver-tients treated with different membranes and found a
sus the 0.565 value estimated after an adjustment for agesignificantly lower proportion of radiologically deter-
and diabetic status.mined bone cysts in the patients treated with synthetic
This study showed a nonsignificant 10% lower RR ofmembranes (PAN) than in those treated with cupro-
death in patients on convective treatments. This is muchphane membrane, but survival without CTS was the
less than the 76% reported in the retrospective study bysame. The Cooperative Group on Dialysis-Associated
Hornberger et al [28]. In a recent analysis of 715 patients,Arthropathy conducted a survey of the patients who had
Woods identified two groups: 252 patients treated exclu-received HD more than 10 years in 19 French centers
[22]. The use of a high-flux dialyzer (PAN) was not associ- sively with low-flux polysulfone and 463 patients treated
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for at least three months and up to five years with high- APPENDIX
flux polysulfone [29]. The patients treated with high-flux Abbreviations used in this article are: CI, confidence interval; CTS,
carpal tunnel syndrome; DRA, dialysis-related amyloidosis; ESRD,polysulfone experienced significantly lower mortality (21
end-stage renal disease; HD, hemodialysis; HDF, hemodiafiltration;vs. 36 per 1,000 years) and had a significantly better
HF, hemofiltration; PAN, polyacrylonitrile; RR, relative risk; RRT,
probability of survival at five years (90% vs. 60%). In a renal replacement therapy.
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